68 related articles for article (PubMed ID: 15882269)
1. Impaired EDHF-mediated vasodilation and function of endothelial Ca-activated K channels in uremic rats.
Köhler R; Eichler I; Schönfelder H; Grgic I; Heinau P; Si H; Hoyer J
Kidney Int; 2005 Jun; 67(6):2280-7. PubMed ID: 15882269
[TBL] [Abstract][Full Text] [Related]
2. EDHF: spreading the influence of the endothelium.
Garland CJ; Hiley CR; Dora KA
Br J Pharmacol; 2011 Oct; 164(3):839-52. PubMed ID: 21133895
[TBL] [Abstract][Full Text] [Related]
3. Impaired small-conductance Ca2+-activated K+ channel-dependent EDHF responses in Type II diabetic ZDF rats.
Burnham MP; Johnson IT; Weston AH
Br J Pharmacol; 2006 Jun; 148(4):434-41. PubMed ID: 16682967
[TBL] [Abstract][Full Text] [Related]
4. Interactions between renal vascular resistance and endothelium-derived hyperpolarization in hypertensive rats in vivo.
Stannov SU; Brasen JC; Salomonsson M; Holstein-Rathlou NH; Sorensen CM
Physiol Rep; 2019 Aug; 7(15):e14168. PubMed ID: 31368238
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologic targeting of endothelial Ca
Mathew John C; Khaddaj Mallat R; George G; Kim T; Mishra RC; Braun AP
Channels (Austin); 2018 Jan; 12(1):126-136. PubMed ID: 29577810
[TBL] [Abstract][Full Text] [Related]
6. Back to the salt mines-- endothelial dysfunction in hypertension and compensatory role of endothelium-derived hyperpolarizing factor (EDHF).
Katusic ZS
J Physiol; 2002 Aug; 543(Pt 1):1. PubMed ID: 12181276
[No Abstract] [Full Text] [Related]
7. Changes in vascular reactivity and endothelial Ca
Taylor MS; Choi CS; Bayazid L; Glosemeyer KE; Baker CCP; Weber DS
Microcirculation; 2017 Apr; 24(3):. PubMed ID: 28106317
[TBL] [Abstract][Full Text] [Related]
8. Non-neuronal cell-derived acetylcholine, a key modulator of the vascular endothelial function in health and disease.
Sonobe T; Kakinuma Y
Front Cardiovasc Med; 2024; 11():1388528. PubMed ID: 38812748
[TBL] [Abstract][Full Text] [Related]
9. Pathogenic soluble tau peptide disrupts endothelial calcium signaling and vasodilation in the brain microvasculature.
Freeman K; Sackheim AM; Mughal A; Koide M; Bonson G; Ebner G; Hennig G; Lockette W; Nelson MT
bioRxiv; 2023 Sep; ():. PubMed ID: 37609200
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitors (HDACi) increase expression of KCa2.3 (SK3) in primary microvascular endothelial cells.
Kolski-Andreaco A; Balut CM; Bertuccio CA; Wilson AS; Rivers WM; Liu X; Gandley RE; Straub AC; Butterworth MB; Binion D; Devor DC
Am J Physiol Cell Physiol; 2022 Mar; 322(3):C338-C353. PubMed ID: 35044858
[TBL] [Abstract][Full Text] [Related]
11. Modulation of Cardiovascular Function in Primary Hypertension in Rat by SKA-31, an Activator of
Kloza M; Baranowska-Kuczko M; Toczek M; Kusaczuk M; Sadowska O; Kasacka I; Kozłowska H
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31450834
[TBL] [Abstract][Full Text] [Related]
12. Nitric Oxide Resistance Reduces Arteriovenous Fistula Maturation in Chronic Kidney Disease in Rats.
Geenen IL; Kolk FF; Molin DG; Wagenaar A; Compeer MG; Tordoir JH; Schurink GW; De Mey JG; Post MJ
PLoS One; 2016; 11(1):e0146212. PubMed ID: 26727368
[TBL] [Abstract][Full Text] [Related]
13. Modulation of K(Ca)3.1 channels by eicosanoids, omega-3 fatty acids, and molecular determinants.
Kacik M; Oliván-Viguera A; Köhler R
PLoS One; 2014; 9(11):e112081. PubMed ID: 25372486
[TBL] [Abstract][Full Text] [Related]
14. AKAP150-dependent cooperative TRPV4 channel gating is central to endothelium-dependent vasodilation and is disrupted in hypertension.
Sonkusare SK; Dalsgaard T; Bonev AD; Hill-Eubanks DC; Kotlikoff MI; Scott JD; Santana LF; Nelson MT
Sci Signal; 2014 Jul; 7(333):ra66. PubMed ID: 25005230
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of endothelial dysfunction in resistance arteries from patients with end-stage renal disease.
Luksha L; Stenvinkel P; Hammarqvist F; Carrero JJ; Davidge ST; Kublickiene K
PLoS One; 2012; 7(4):e36056. PubMed ID: 22563439
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological activation of KCa3.1/KCa2.3 channels produces endothelial hyperpolarization and lowers blood pressure in conscious dogs.
Damkjaer M; Nielsen G; Bodendiek S; Staehr M; Gramsbergen JB; de Wit C; Jensen BL; Simonsen U; Bie P; Wulff H; Köhler R
Br J Pharmacol; 2012 Jan; 165(1):223-34. PubMed ID: 21699504
[TBL] [Abstract][Full Text] [Related]
17. Vascular KCa-channels as therapeutic targets in hypertension and restenosis disease.
Köhler R; Kaistha BP; Wulff H
Expert Opin Ther Targets; 2010 Feb; 14(2):143-55. PubMed ID: 20055714
[TBL] [Abstract][Full Text] [Related]
18. Endothelial Ca+-activated K+ channels in normal and impaired EDHF-dilator responses--relevance to cardiovascular pathologies and drug discovery.
Grgic I; Kaistha BP; Hoyer J; Köhler R
Br J Pharmacol; 2009 Jun; 157(4):509-26. PubMed ID: 19302590
[TBL] [Abstract][Full Text] [Related]
19. Calcium-activated potassium channels and endothelial dysfunction: therapeutic options?
Félétou M
Br J Pharmacol; 2009 Feb; 156(4):545-62. PubMed ID: 19187341
[TBL] [Abstract][Full Text] [Related]
20. Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure.
Sankaranarayanan A; Raman G; Busch C; Schultz T; Zimin PI; Hoyer J; Köhler R; Wulff H
Mol Pharmacol; 2009 Feb; 75(2):281-95. PubMed ID: 18955585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
